



(51) International Patent Classification:

A61K 31/4355 (2006.01) **A61P 25/18** (2006.01)
A61K 31/4365 (2006.01) **A61P 25/24** (2006.01)
A61K 31/437 (2006.01) **A61P 25/28** (2006.01)
A61K 31/497 (2006.01) **C07D 471/04** (2006.01)
A61K 31/506 (2006.01) **C07D 491/048** (2006.01)
A61K 31/513 (2006.01) **C07D 495/04** (2006.01)
A61K 31/519 (2006.01) **C07D 513/04** (2006.01)
A61P 25/16 (2006.01) **C07D 519/00** (2006.01)

(21) International Application Number:

PCT/IB2015/052594

(22) International Filing Date:

9 April 2015 (09.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/984,070 25 April 2014 (25.04.2014) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: GRAY, David Lawrence Firman; 26 Orion Way, Groton, Massachusetts 01450 (US). **ZHANG, Lei**; 75 Bourne Street, Auburndale, Massachusetts 02466 (US). **DAVOREN, Jennifer Elizabeth**; 2456 Massachusetts Ave #105, Cambridge, Massachusetts 02140 (US). **DOUNAY, Amy Beth**; 5725 Astoria Way, Colorado Springs, Colorado 80919 (US). **EFREMOV, Ivan Viktorovich**; 83 Payson Road, Brookline, Massachusetts 02467 (US). **MENTE, Scot Richard**; 48 Arlmont Street, Arlington, Massachusetts 02476 (US). **SUBRAMANYAM, Chakrapani**; 314 Great Pond Road, South Glastonbury, Connecticut 06073 (US).

(74) Agent: OLSON, A. Dean; Pfizer Worldwide Research & Development, Eastern Point Road MS8260-2141, Groton, Connecticut 06340 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with amended claims (Art. 19(1))*

(54) Title: HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS



(57) Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.